Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the Credit Suisse 25th Annual Healthcare Conference on Tuesday, November 8, 2016, at 10:30 a.m. Mountain time (9:30 a.m. Pacific time) in Scottsdale, AZ, where he will provide an overview of Ignyta, review the company’s robust pipeline of molecularly targeted therapies, and summarize company highlights for the third quarter of 2016.
A webcast of the presentation will be available during the presentation in the Investors section of the company's website at https://www.ignyta.com/investors/, and will be archived and available at that site for 14 days.
About Ignyta, Inc.
Blazing a New Future for Patients with Cancer™
At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class and best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.
For more information, please visit: www.ignyta.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006367/en/Business Wire
Last updated on: 01/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.